Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma By Ogkologos - January 21, 2025 852 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a substudy 02C of the KEYMAKER-U02 trial Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR What to Know About Cancer Clinical Trial Matching Programs March 14, 2023 Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast December 2, 2020 EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan October 23, 2020 Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... December 11, 2023 Load more HOT NEWS Dear Prime Minister: “Please don’t delay action again, we’re counting on... Motivational Speaker Shares Her 11-Year Battle With Breast Cancer In New... Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... Breast Cancer Patient Devotes Her Time to Driving Others to Treatment
